Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD)
Status: Recruiting
Location: See all (4) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
IRIS-CKD is an implementation study to improve guideline-recommended screening of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Adults with type 2 diabetes (T2D)
• Receiving primary care within the healthcare system, Primary Care Provider (PCP) visit within the past 24 months (any PCP provider, including APP).
• Lack of estimated glomerular filtration rate (eGFR) and/or urine albumin- creatinine ratio (UACR) measurement in the prior 15 months within the EHR
Locations
United States
Alabama
University of Alabama
RECRUITING
Birmingham
Minnesota
Essentia Health
RECRUITING
Duluth
North Carolina
Duke University
RECRUITING
Durham
Texas
Baylor Scott & White
NOT_YET_RECRUITING
Temple
Contact Information
Primary
Gretchen Sanders, MSN
gretchen.sanders@duke.edu
919 6687829
Backup
Monica Leyva, MS
monica.leyva@duke.edu
Time Frame
Start Date: 2025-10-28
Estimated Completion Date: 2027-04-01
Participants
Target number of participants: 750
Treatments
Active_comparator: (IRIS-CKD Screening Program): Home Kit
Home Kit: a kit delivered to participants home with instructions to complete eGFR (fingerstick) and/or UACR (urine sample) testing, depending on which lab(s) are missing at baseline.
Active_comparator: (IRIS-CKD Screening Program): Standard Lab Testing
Standard Laboratory Testing: a traditional order will be placed into the Electronic Health Record (EHR) for eGFR and/or UACR testing, depending on which lab(s) are missing at baseline.
Related Therapeutic Areas
Sponsors
Collaborators: Boehringer Ingelheim, Eli Lilly and Company, Bayer
Leads: Duke University